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Although tyrosine phosphorylation of extracellular
proteins has been reported to occur extensively
in vivo, no secreted protein tyrosine kinase has
been identified. As a result, investigation of the po-
tential role of extracellular tyrosine phosphorylation
in physiological and pathological tissue regulation
has not been possible. Here, we show that VLK, a pu-
tative protein kinase previously shown to be essen-
tial in embryonic development, is a secreted protein
kinase, with preference for tyrosine, that phosphory-
lates a broad range of secreted and ER-resident
substrate proteins. We find that VLK is rapidly and
quantitatively secreted from platelets in response
to stimuli and can tyrosine phosphorylate coreleased
proteins utilizing endogenous as well as exogenous
ATP sources. We propose that discovery of VLK ac-
tivity provides an explanation for the extensive and
conserved pattern of extracellular tyrosine phospho-
phorylation seen in vivo, and extends the importance
of regulated tyrosine phosphorylation into the extra-
cellular environment.
INTRODUCTION
An extraordinary and little-recognized observation has emerged
from analysis of the mammalian phosphoproteome: a substan-
tial portion of secreted or extracellular proteins have been re-
ported to contain phosphotyrosine (Hornbeck et al., 2012), but,
to date, no secreted tyrosine kinase has been identified. Tyrosine
phosphorylation of a wide range of extracellular matrix (ECM)
and pericellular proteins has been reported in high-throughput
liquid chromatography tandem mass spectrometry (LC MS/
MS) analysis of tissue samples of both healthy and diseased tis-
sues (Hornbeck et al., 2012). In many instances, tyrosine phos-phorylation at these sites has been reported in multiple indepen-
dent studies using material from both cultured cell and primary
tissue samples (Ballif et al., 2008; Hornbeck et al., 2012). In light
of the emerging importance of ECM as a dynamically regulated
microenvironment with a fundamental role (Hynes and Naba,
2012; Lu et al., 2011) in the control of cell differentiation, survival,
and function, tyrosine phosphorylation of ECM proteins repre-
sents a potential major new mechanism of tissue regulation.
Phosphorylation of the secreted acidic milk protein casein
has been known for over a century (Tagliabracci et al., 2013;
Yalak and Vogel, 2012), but only in 2012 was the kinase respon-
sible for the serine phosphorylation of casein and other
acidic secreted proteins identified (Tagliabracci et al., 2012).
Fam20C, a Golgi localized protein kinase, is a serine kinase
that phosphorylates both casein and other highly acidic proteins
such as osteopontin and members of the small integrin-binding
ligand, N-linked glycoproteins (SIBLING) family at the target
motif SerXGlu (Tagliabracci et al., 2012). Phosphorylation by
Fam20C in the secretory pathway is robust and essential for
proper biomineralization of bone. The substrate specificity of
FAM20C indicates, however, that it is not likely to account for
the tyrosine phosphorylation of the secreted proteins described
above. The discovery of FAM20C highlighted, however, that the
mammalian secretory kinome may be largely unexplored, with
an unknown number of secreted protein kinases yet to be iden-
tified (Tagliabracci et al., 2013; Yalak and Vogel, 2012).
In many ECM and matricellular proteins, tyrosine phosphory-
lations occur at structurally conserved positions in otherwise
distantly related proteins (Hornbeck et al., 2012), suggesting a
conserved regulatory roles for these modifications The hemo-
pexin domain of matrix metalloproteinases (MMPs) provides a
clear example of this phenomenon. Seven different MMP family
members have been reported to be tyrosine phosphorylated
within their C-terminal hemopexin domains (Figure 1A) (Guo
et al., 2008; Hornbeck et al., 2012; Raijmakers et al., 2010;
Rikova et al., 2007). In each case, the phosphotyrosine is found
at a conserved b-bulge in blade 2 of the hemopexin 4-blade
propeller structure (Figure 1B). Strikingly, phosphorylation at anCell 158, 1033–1044, August 28, 2014 ª2014 Elsevier Inc. 1033
Figure 1. Conserved Position of Phosphorylated Tyrosine in
Hemopexin Domains Reported In Vivo in Phosphosite Compendium
(A) All sites shown are at orthologous positions within the hemopexin domain
as defined by primary sequence conservation.
(B) Hemopexin domain structures for MMP1 (MMDB ID: 30864) (Jozic et al.,
2005), MMP13 (MMDB ID: 57090) (Gomis-Ru¨th et al., 1996) and hemopexin
(MMDB ID:56395) (Faber et al., 1995). Yellow arrow indicates reported site of
tyrosine phosphorylation (Tyr360 in hMMP1, Tyr366 in hMMP13, Tyr341 in
hHPX) (Hornbeck et al., 2012; Raijmakers et al., 2010).
See also Figure S1.identical position is alsoseen in lubricin (Rinschenet al., 2010) and
hemopexin (Rinschen et al., 2010), proteinswhich contain the he-
mopexin domain structure but which are only distantly related to
MMPs (Figure 1B).While the structural conservationof these tyro-
sine phosphorylations is intriguing, in the absence of any known
secreted tyrosine kinases there has been no way to study the
regulation or role of this novel class of tyrosine phosphorylations.
To understand the regulation and significance of the tyrosine
phosphorylation of secreted proteins, we re-examined the exist-
ing kinome and associated literature for unrecognized secreted
protein kinases. The putative protein kinase VLK/PKDCC (here-
after VLK) emerged from this search as a promising candidate
for a secreted tyrosine kinase. The Vlk gene (also known as
sgk493, adtk1, and AW548124) was cloned as a putative protein
kinase expressed in differentiating embryonic stem cells (Gon-1034 Cell 158, 1033–1044, August 28, 2014 ª2014 Elsevier Inc.c¸alves et al., 2011; Imuta et al., 2009; Kinoshita et al., 2009).
Vlk/ mice die within one day of birth, with severe defects in
morphogenesis in multiple tissues, indicating that Vlk is essential
for patterning at organogenesis stages (Gonc¸alves et al., 2011;
Imuta et al., 2009; Kinoshita et al., 2009; Probst et al., 2013).
Vlk encodes a protein with clear homology to protein kinases
(Figures 2A, and S2), but lacking recognizable homology in
kinase subdomains V, IX, X, and X1 (Hanks, 2003; Kinoshita
et al., 2009), and by primary sequence is not distinguishable as
a member of the major serine-threonine, tyrosine, or dual spec-
ificity subsets of intracellular protein kinases (Figure S2A).
Strikingly, VLK contains a predicted hydrophobic sequence
near the N terminus that we find to be recognized as a signal
sequence by multiple signal sequence prediction algorithms
(Horton et al., 2007; Petersen et al., 2011) (Figure 2A).
We demonstrate here that VLK is a secreted protein kinase
with preference for tyrosine residues and that it phosphorylates
secreted proteins at sites identical to many of those previously
reported to occur in vivo. Expression of VLK results in the tyro-
sine phosphorylation of both secreted and ER/Golgi resident
proteins, and these phosphorylations are dependent on the
signal peptide as well as the active kinase domain of VLK. VLK
is constitutively secreted by mammalian cell lines and is highly
expressed in human platelets, localized to secretory granules,
and quantitatively released following platelet degranulation.
Furthermore, tyrosine phosphorylation of proteins secreted
from stimulated platelets is VLK dependent and can be sup-
ported by endogenous secreted ATP. These observations
identify VLK as the first secreted protein tyrosine kinase, which
can act not only in the secretory pathway but also following its
regulated release outside the cell.
RESULTS
VLK Localizes to the Secretory Pathway and
Is Glycosylated
To test localization of VLK to the lumenal compartment of the
secretory pathway, we expressed VLK in 293T cells and treated
detergent-free cell lysateswith proteinaseK (PK) alone or in com-
bination with NP40. Proteins localizing to the cytoplasm, like
GFP, are degraded by PK treatment, while proteins localized to
the lumenal side of the ER or Golgi are protected by the lumenal
membrane in the absence of detergent (Brown et al., 1987). VLK
was not degraded by PK alone, but was completely degraded
with the addition of NP40 (Figure 2B), indicating that VLK local-
izes to a membrane protected subcellular compartment. To
test if the predicted N-terminal signal peptide in VLK is respon-
sible for its localization, we generated a tagged construct lacking
the first 23 amino acids (VLKSP). VLKSP was completely
degraded following PK treatment in the absence of detergent
(Figure 2C), demonstrating signal-peptide dependent localiza-
tion of VLK to the secretory pathway. Furthermore, full-length
VLK, but not VLKSP was found in the conditioned media (CM)
of transfected cells (Figure 2D) confirming the requirement of
the VLK signal peptide for secretion. Moreover VLK, but not
VLKSP, is strongly phosphorylated on tyrosine (Figure 2D).
VLK contains five potential sites for N-linked glycosylation
(AsnXSer/Thr). To test if VLK is glycosylated in the secretory
Figure 2. VLK Is Constitutively Secreted and
Its Glycosylation and Secretory Pathway
Localization Are Signal Peptide Dependent
(A) Sequence of mouse VLK. Signal peptide is
indicated by double underline, signal-peptide
cleavage site with an arrow. Sites of point muta-
tions discussed in the text are marked in bold with
asterisk, the ProGly rich domain is marked by
dashed underline. The predicted kinase region is
underlined in solid black.
(B) Detergent-free lysates of 293T cells over-
expressing GFP or VLK were treated with protein-
ase K (PK) alone or in combination with NP40.
(C) Detergent-free lysates of HepG2 cells coex-
pressing VLK and VLKSP were treated with pro-
teinase K (PK) alone or in combination with NP40.
(D) VLK expression was determined in lysates and
CM of 293T cells overexpressing VLK or VLKSP.
Tyrosine phosphorylation was detected following
VLK immunoprecipitation.
(E) Cell lysates expressing either VLK or VLKSP
were treated with PNGase to remove N-linked
glycosylations.
(F) Lysates of HepG2 cells were treated with PK
alone or in combination with NP40, and endoge-
nous VLK detected by western blot. Cytoplasmic
actin was measured as a marker of cytoplasmic
protein.
(G) VLK expression and secretion was detected in
lysates and CM of brefeldin A treated HepG2 cells.
(H) VLK expression was detected in lysates (Lys)
and CM of HepG2 cells treated with brefeldin A,
before and after ultracentrifugation.
(I) VLK protein levels were determined in CM
of HepG2 cells stably transduced with either a
scrambled shRNA (c) or two independent shRNAs
targeting Vlk (#2, #5). Percentage of protein
expression was quantified using ImageJ. See also
Figure S2.pathway, we treated lysates of cells expressing either VLK or
VLKSP with PNGase F, which removes N-linked oligosaccha-
rides. A shift in gel migration was observed for VLK, indicating
the presence of N-linked glycosylations, whereas VLKSP was
unaffected (Figure 2E).
Endogenous VLK Is Secreted into CM
We next examined the localization of endogenous VLK to the
secretory pathway. Preliminary screening established detection
of endogenousVLK in several established lines,with high expres-
sion seen in HepG2 liver hepatoma cells. As for ectopically ex-
pressed VLK, endogenous VLK in HepG2 cells was not degraded
by PK treatment in the absence of NP40 (Figure 2F). ProgressiveCell 158, 1033–1044and quantitative accumulation of endoge-
nous VLK was detected in the CM of
HepG2 cells (Figure 2G). VLK secretion
was abrogated by the addition of the ER/
Golgi protein transport inhibitor brefeldin
A, with a corresponding increase in cell-
associated VLK (Figure 2G). Secreted
VLK is found in the supernatant of HepG2conditioned medium centrifuged at 100,000 3 g, indicating that
it is not associatedwithmicrovesicular or exosomeparticles (Fig-
ure 2H). The specificity of antibody detection of endogenous VLK
was confirmedby lentiviral-mediated knock-down ofVlkwith two
independent shRNA constructs (Figure 2I). These data establish
that endogenous VLK is quantitatively localized to the secretory
pathway, and is constitutively released from cultured cells.
VLK Phosphorylates Substrates following Stimulated
Release from Platelets
To explore the possibility that VLK secretion is physiologically
regulated, we examined the ligand stimulated degranulation
of human platelets. VLK is abundantly expressed in platelets, August 28, 2014 ª2014 Elsevier Inc. 1035
Figure 3. VLK Is Secreted from Platelets
and Is Responsible for Tyrosine Phosphory-
lation in the Platelet Releasate
(A) Freshly isolated human platelets were treated
with either 0.2 mM PMA or 0.5 mM TRAP for 15 min.
After centrifugation to remove cells, cell-free relea-
sate was incubated for an additional 15 min in the
presence or absence of 2 mM ATP (Sup.+ATP).
Black arrow indicates phospho-tyrosine band
comigrating with VLK. Asterisks mark bands that
change in releasate with stimulation and ATP.
(B) Tyrosine phosphorylation is dependent on VLK
and on endogenous ATP. Left Panel: Following
platelet stimulation with TRAP for 4 min, VLK was
depleted from releasates by incubation with anti-
VLK or control IgG and protein A sepharose for the
indicated times, and then phosphorylation was
stimulated by exogenous 2 mM ATP addition
(+ATP) for 15 min. Note that some VLK dependent
phosphorylation occurs in the absence of exoge-
nous ATP, presumably due to endogenous
secreted ATP. Right: platelets were stimulated
with TRAP in the presence of 100 Units of apyrase
to degrade endogenous released ATP. After 4 min
stimulation with TRAP, platelets were cleared by
centrifugation and releasate incubated for addi-
tional time indicated, then analyzed by anti-pTyr
western blot. Asterisks indicate bands changing
following treatments.
(C) Immunofluorescence of platelets with anti-VLK
antibody shows puncate staining.
(D) Immunogold-EM staining with anti-VLK local-
izes VLK to alpha granules. Scale bars: (C) 5 mm
and (D) 0.5 mm. See also Figure S3.(Figures 3A and S3A). Stimulation of platelet degranulation with
either the thrombin receptor agonist thrombin receptor activating
peptide (TRAP) (Ahn et al., 1997) or phorbol-12-myristate-13-ac-
etate (PMA) (Rozenvayn and Flaumenhaft, 2003), led to the rapid
release of VLK into the cell supernatant, concomitant with the
release of the alpha granule markers von Willebrand Factor
(vWF) protein and thrombospondin (TSP1) (Harrison and Cramer,
1993) (Figure 3A, 3B). Notably, TRAP stimulation resulted in a dra-
matic decrease in the amount of cell-associatedVLKconcomitant
with the increase of VLK in the cell supernatant, indicating that the
stimulus-dependent release of VLK is nearly complete.
Anti-pTyr immunoblotting of unstimulated versus TRAP stimu-
lated platelets revealed that several tyrosine phosphorylated
proteins are detectable in the releasate. The most prominent of
these secreted phosphotyrosine bands comigrates with VLK,
suggesting that secreted VLK is tyrosine phosphorylated
endogenously in platelets (Figure 3A). Addition of supplemental
ATP to cell-free supernatant released from TRAP or PMA stimu-1036 Cell 158, 1033–1044, August 28, 2014 ª2014 Elsevier Inc.lated platelets resulted in an increase
in tyrosine phosphorylation of releasate
proteins, indicating that tyrosine phos-
phorylation can occur in the extracellular
environment following regulated tyrosine
kinase secretion (Figure 3A). Depletion
of secreted VLK with an anti-VLK anti-body markedly decreased tyrosine phosphorylation following
ATP addition, establishing that secreted VLK phosphorylates
substrates in the extracellular environment (Figure 3B). While
VLK dependent tyrosine phosphorylation was strongly stimu-
lated by ectopic ATP addition, significant tyrosine phosphoryla-
tion of identical bands was seen in the absence of ATP addition
(Figure 3B). Since platelets secrete ATP from dense granules
concomitantly with protein release from alpha granules (McNicol
and Israels, 1999), we examined the effect of depletion of
endogenous coreleased ATP with added apyrase on tyrosine
phosphorylation. Apyrase addition dramatically reduced phos-
phorylation of a set of tyrosine phosphoprotein bands similar
to those reduced by VLK depletion (Figure 3B, marked with
asterisks), indicating that endogenous ATP can support the
tyrosine phosphorylation of protein secreted from platelets
subsequent to degranulation (Figure 3B).
Immunolocalization of VLK in unstimulated platelets by
confocal microscopy shows a punctate pattern consistent with
localization to alpha granules (Figure 3C, Figure S3B), and elec-
tron microscopy confirms VLK localization to these structures
(Figure 3D). Immunohistochemical staining of mouse megakar-
yocytes, which give rise to mature platelets (Italiano et al.,
1999), showed a punctate distribution similar to that seen in
mature human platelets (Figure S3D), suggesting that VLK is
likely synthesized during megakaryocyte development and
distributed to nascent platelets.
VLK Phosphorylates a Variety of Extracellular Proteins
Existing phosphoproteomic data sets pointed to a wide range of
secreted proteins that are phosphorylated on tyrosine in vivo.
We used these data as a guide to the testing of candidate sub-
strates for VLK phosphorylation, with a focus on phosphoryla-
tions that had been reported at sites conserved across broad
sets of related proteins. MMPs were strong candidates in this
regard, due to the numerous reports of tyrosine phosphoryla-
tion in vivo of the hemopexin domain in a subset of MMPs
(Figure 1A). Coexpression of VLK with hMMP1, hMMP13,
hMMP14, hMMP19 and bMMP27 in each case resulted in tyro-
sine phosphorylation of the MMP (Figure 4A and Figure S4A).
Additional substrates, structurally unrelated to MMPs, but sug-
gested as potential substrates by reports of tyrosine phosphor-
ylation in vivo (laminin A1, FUT8, TNFSF10) (Hornbeck et al.,
2012), were also phosphorylated when coexpressed with VLK
(Figure 4A and Figure S4A), suggesting that VLK substrates
are not limited to a single class of proteins or structural motifs.
Phosphorylation of coexpressed proteins was not seen with
VLKmutated at a key residue (Lys166) in the predicted ATP bind-
ing site (VLKKM) (Kinoshita et al., 2009), or with VLKSP (Figures
4A and 4B). In addition to its predicted kinase domain and signal
peptide, a distinctive feature of VLK, conserved across mamma-
lian orthologs, is a proline glycine (PG) rich domain N-terminal
to the start of the kinase domain (Figure 2A). Deletion of this
conserved PG rich region (VLKDPG) also eliminates the phos-
phorylation of coexpressed substrates (Figure S4B), as well as
of VLKDPG itself (Figure S4C). To examine whether endogenous,
as well as ectopically expressed VLK, could support tyrosine
phosphorylation of a secreted protein, we tested the effect of
downregulation of endogenous VLK on MMP13 phosphoryla-
tion. shRNA-mediated downregulation of VLK reduced expres-
sion of endogenous VLK in 293T cells, with a concomitant
reduction in the tyrosine phosphorylation of tagged MMP13 in
the CM of transfected cells (Figure 4C).
MMP1 has been reported to be tyrosine phosphorylated in
leukocytes in vivo on tyrosine Y360 (Raijmakers et al., 2010). Ex-
amination of material released from platelets established that
endogenous MMP1 is tyrosine phosphorylated in platelets, and
is released in response to stimulation by TRAP (Figure 4D). To
determine whether VLK can phosphorylate MMP1 on the same
site reported in vivo, we performed LC-MS/MS on a protein sam-
ple of MMP1 that had been coexpressed with VLK, and found
that Y360 is the major tyrosine phosphorylated site in MMP1 un-
der these conditions (Figure S4D) indicating that the principle site
of MMP1 phosphorylation by VLK is identical to that reported
in vivo. Expression of MMP1 in which Y360 was mutated to
phenylalanine showed only partially reduced tyrosine phosphor-
ylation in the presence of VLK, however, indicating that addi-tional sites are tyrosine phosphorylated (Figure S4E), apparently
below the detection limit of tandemmass spectrometry. LC-MS/
MS analysis also identified phosphorylated serine (S57) and
threonine (T274) residues in MMP1 (Figure S4D); raising the pos-
sibility that VLKmodifies serine and threonine as well as tyrosine
residues in MMP1.
VLK Kinase Activity Is Necessary for Its Release from
the Cell
Wild-type VLK accumulates in the CM of cells in which it is
ectopically expressed. In striking contrast, very little VLKKM is
secreted into CM (Figure 4E), suggesting that VLK kinase activity
is necessary for its secretion. To confirm the importance of the
kinase domain in VLK secretion, we generated two additional
VLKmutants in which highly conserved residues in the predicted
kinase domain were modified (VLKEA, VLKDA). Like VLKKM,
VLKEA, and VLKDA failed to autophosphorylate on tyrosine, and
lost its ability to phosphorylate substrates likeMMP1 (FigureS4F,
upper and S4H, left). Secretion of VLKEA or VLKDA into CM was
also dramatically reduced relative to wild-type VLK (Figures 4E
and S4G). Examination of PK sensitivity of wild-type and kinase
dead VLK mutants in detergent-free cell lysates demonstrated
that themutants are localized to the ER/Golgi lumen as efficiently
as wild-type VLK (Figure 4E). VLK has been previously reported
to be phosphorylated at Y148 (Kinoshita et al., 2009); mutation of
this site to phenylalanine does not alter VLK secretion, indicating
that autophosphorylation at this site is not involved in the control
of VLK progression through the secretory pathway (Figure 4E).
Mutation of Y148 also had no effect on the ability of VLK to phos-
phorylate coexpressed substrates (Figure S4I, upper). Tyrosine
phosphorylation of VLK was still seen in the Y148F mutant, but
not in the kinase dead VLK constructs, suggesting the existence
of additional VLK autophosphorylation sites (Figures S4F and
S4I, lower). These data indicate that VLK kinase activity is impor-
tant for its release from the cell, but whether this is due to auto-
phosphorylation on uncharacterized sites or to phosphorylation
of other substrates in the secretory pathway is not clear.
VLK Phosphorylates Endogenous Proteins in the
Secretory Pathway
To define the spectrum of VLK-dependent phosphorylation of
endogenous proteins, we generated K4 fibroblasts stably ex-
pressing either VLK or VLKKM. Expression of wild-type VLK,
but not VLKKM, resulted in a dramatic increase in total cellular
tyrosine phosphoprotein (Figure 5A). Because VLK diverges
strongly from cytosolic tyrosine protein kinases in its kinase
domain, we expected that VLK kinase activity would not be
reduced by inhibitors of cytosolic tyrosine kinases. Treatment
of cells with the broad spectrum tyrosine kinase inhibitor dasati-
nib (Shah et al., 2004) strongly reduced tyrosine phosphoprotein
bands shared among GFP K4, VLK K4, and VLKKM K4 cells, but
had no effect on bands unique to VLK K4 cells (Figure 5A). Tyro-
sine phosphorylation in the CM of K4 cells was exclusively de-
tected following VLK but not VLKKM overexpression (Figure 5B),
and the accumulation of these proteins in CM was abrogated by
treatment with brefeldin A (Figure S5C). VLK-dependent phos-
phorylations were, like VLK itself, protected from PK treatment
in detergent-free lysates (Figure S5A). No changes in threonineCell 158, 1033–1044, August 28, 2014 ª2014 Elsevier Inc. 1037
Figure 4. VLK Phosphorylates Secreted and Transmembrane Substrates
(A) 293T cells were cotransfected with the indicated candidate substrate and either VLK wild-type or VLKKM. Tyrosine phosphorylation was detected following
immunoprecipitation of candidate substrates from cell lysates.
(B) Tyrosine phosphorylation was analyzed in lysates of 293T cells coexpressing MMP1 and VLK, VLKKM, or VLKSP following MMP1 immunoprecipitation.
(C) MMP13 was overexpressed in 293T cells stably transduced with either a scrambled shRNA or an shRNA targeting VLK (#5). Tyrosine phosphorylation was
examined in CM following MMP13 immunoprecipitation. VLK expression was determined in cell lysates (Lys.)
(D) Freshly isolated human platelets were treated with 0.5 mM TRAP for 15 min. After centrifugation to remove cells, protein expression and tyrosine phos-
phorylation were determined in pellets and supernatants.
(E) Detergent-free lysates of 293T cells expressing the indicated VLK constructs were treated with PK alone or in combination with NP40. See also Figure S4.or serine phosphorylations in K4 cell lysates were seen following
VLK overexpression (Figure S5B) and no serine or threonine
phosphorylations at all could be detected in the CM of K4 cells
(Figure S5C). The predominant detectable change in overall pro-
tein phosphorylation associated with VLK expression therefore
appears to be phosphotyrosine.1038 Cell 158, 1033–1044, August 28, 2014 ª2014 Elsevier Inc.To identify endogenous substrates for VLK, we did antiphos-
photyrosine (anti-pTyr) immunoprecipitation of tryptic digests
of total cell protein and total CM from VLK expressing cells, fol-
lowed by identification of phosphopeptides by LC-MS/MS
(Breitkopf and Asara, 2012). One hundred and forty distinct tyro-
sine phosphopeptides were identified, of which 48 tyrosine
Figure 5. VLK Expression Enhances Cellular and Secreted Tyrosine
Phosphorylation
(A) K4 synoviocytes stably overexpressing GFP, VLK, or VLKKM were treated
with 100 nM dasatinib for 6 hr. Extent of tyrosine phosphorylation in
lysates was assessed by immunoblotting. Asterisks indicate VLK-dependent
phosphorylations.
(B) Tyrosine phosphorylation was detected in TCA-precipitated CM of K4
synoviocytes overexpressing VLK or VLKKM. See also Figure S5.phosphopeptides mapped either to proteins containing canoni-
cal signal peptides or to the extracellular domains of transmem-
brane proteins (Table 1 andData S1). In addition, several tyrosine
phosphopeptides were exclusively detected in CM (Table 1).
Of the 48 secretory/extracellular tyrosine phosphopeptides
identified, 11 have been identified in biosamples from in vivo
tissue (Hornbeck et al., 2012). The most frequently detected
phosphopeptide in VLK expressing K4 cells occurred at Tyr66
in ERP29, an ER chaperone that is the mammalian homolog
of the Drosophila developmental mutation windbeutel. Tyr66,
conserved in windbeutel, is essential for chaperone function
(Barnewitz et al., 2004), and has been found to be phosphory-
lated both in vivo and in a wide range of cell lines in 366 separate
MS-MS analyses (Bai et al., 2012; Ding et al., 2011; Gu et al.,
2011; Guo et al., 2008; Hornbeck et al., 2012; Rikova et al.,
2007). These observations indicate that the tyrosine phosphory-
lation of specific sites in secretory pathway proteins occurs
in vivo under endogenous conditions of VLK expression as well
as in the presence of ectopic VLK. Comparison of tyrosine phos-
phorylation in cells expressing wild-type VLK or VLKKM using
SILAC analysis established that only proteins in the secretory
pathway, and not cytoplasmic proteins, showed increased
tyrosine phosphorylation in the presence of wild-type VLK, con-
firming that VLK is likely to act specifically on proteins in the
secretory pathway (Table S1). To further confirm that the tyrosine
phosphorylation in secretory pathway proteins was VLK depen-
dent, we performed immunoblot analysis for several candidate
VLK substrates on phospho-tyrosine immunoprecipitation of
lysates from K4 VLK or K4 VLKKM cells (Figure S5D). In each
case, tyrosine phosphorylation was seen only in material fromcells expressing active VLK. Systematic comparison of tyrosine
phosphopeptides identified in cells expressing wild-type VLK
and cells expressing VLKKM established that every peptide an-
notated as deriving from a secreted protein or from the extracel-
lular domain of a transmembrane protein was detected only in
cells expressing wild-type VLK (data not shown).
To confirm that tyrosine kinase activity is intrinsic to VLK, and
is inactivated by mutation of Lys166, wild-type and mutant pro-
teins were expressed and purified in a baculoviral expression
system. Wild-type, but not mutant, VLK protein, phosphorylated
both a peptide derived from the hemopexin domain of MMP1
(HpxPeptide) or a peptide designed as an optimal substrate
based on tyrosine phosphopeptides identified in VLK expressing
cells (Ypeptide) (Figure 6A). Wild-type, but not mutant, VLK
protein also directly phosphorylated purified ERP29 protein,
and showed dramatically reduced phosphorylation of mutant
ERP29 lacking the sites of tyrosine phosphorylation identified
in VLK expressing cells and in vivo (Tyr64/Tyr66) (Figure 6B).
Kinase activity was optimal in the presence of a combination
of Mg2+ and Ca2+, and was only weakly supported by Mn2+ (Fig-
ure S6). The specific activity of VLK purified from the baculoviral
system, 0.2 nmol/min/mg, was 10- to 100-fold lower than ac-
tivities typically observed for cytoplasmic tyrosine kinases. VLK
phosphorylated peptides in which the tyrosine residue was
replaced with serine (Speptide) or threonine (Tpeptide) with
reduced efficiency (Figure 6A). These data establish that purified
VLK has intrinsic kinase activity with a preference for tyrosine,
and can phosphorylate ERP29 on the same tyrosines shown to
be phosphorylated in VLK-expressing cells and in vivo.
DISCUSSION
There Is a Broad Range of Potential Substrates for VLK
In Vitro and In Vivo
Examination of an unbiased set of secreted and lumenal tyrosine
phosphoproteins from VLK expressing cells reveals a broad set
of VLK substrates, many of which correspond to tyrosine phos-
phorylations in secreted proteins seen in vivo (Table 1). While our
initial studies focused on theMMPs as candidate substrates, the
broader set of substrates we find in VLK-expressing fibroblasts
do not share evident structural features with MMP hemopexin
domains or with one another. They also do not share any clear
local motif surrounding the phosphorylation site, in contrast to
the secreted serine kinase FAM20C, which targets the local motif
SerXGlu (Tagliabracci et al., 2012). The basis for substrate
recognition by the VLK kinase activity therefore remains puz-
zling. Phosphorylation by VLK may depend on some combina-
tion of surface exposure of tyrosine, juxtaposition of specific
amino acids in the tertiary structure around the phosphorylation
site, and/or association of VLK with multiple targeting subunits
that direct the kinase activity to distinct classes of substrates.
Ectopic expression of VLK in fibroblasts substantially alters
total cellular protein tyrosine phosphorylation (Figure 5A), estab-
lishing that VLK-dependent phosphorylation in cells is quantita-
tively similar to the sum of activities of endogenous cytosolic
tyrosine kinases. The low activity of purified VLK protein there-
fore seems paradoxical and may reflect inefficient folding or di-
sulfide bond formation in the ER in the baculovirus/S9 system,Cell 158, 1033–1044, August 28, 2014 ª2014 Elsevier Inc. 1039
Table 1. Identification of Tyrosine Phosphopeptides in Secreted Proteins and Extracellular Domains in VLK Expressing Cells
Protein Name Positions within Protein Endogenous Phosphorylation Reported
Mesencephalic astrocyte-derived neurotrophic factor 76 Y(21)
Collagen alpha-1(I) chain 1215; 1216
collagen prolyl 4-hydroxylase beta (P4HB) 94; 268 Y(1)
Prolyl 4-hydroxylase subunit alpha-2 79 Y(1 TC)
Osteopontin 165
Follistatin-related protein 1 286;251
Insulin-like growth factor-binding protein 3 190
Insulin-like growth factor-binding protein 10 221
Insulin-like growth factor-binding protein 7 201
Protein kinase domain-containing protein, cytoplasmic (VLK) 64
Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase 301
Peroxiredoxin-4 266
Lysozyme-like protein 1 106
Serine protease 23 131 Y(1 TC)
Melanoma inhibitory activity protein 3 969
Golgi integral membrane protein 4 407;379 Y (9)
Polypeptide N-acetylgalactosaminyltransferase 5 68
Proadrenomedullin 52
Secretogranin-2 457 Y(12)
Endoplasmic reticulum resident protein 44 395
Cysteine-rich with EGF-like domain protein 2 68;
Protein disulfide-isomerase A3 100; 445
Endoplasmic reticulum resident protein 29 64; 66 Y(15);Y(365)




Protein canopy homolog 2 71
Protein canopy homolog 3 110
Multiple inositol polyphosphate phosphatase 1 46
Transmembrane emp24 domain-containing protein 10 135
CRELD2 68
Retina-specific copper amine oxidase 488 Y(1 TC)
prosaposin 187
Galectin-3-binding protein 446
78 kDa glucose-regulated protein (HSPA5) 65; 635
Alpha-2-macroglobulin receptor-associated protein 336 Y(1)
Calumenin 275 Y(60)
Angiopoietin-related protein 5 165
Amyloid beta A4 protein 588
SorCS2 746; 574
Epsilon-sarcoglycan 38 Y(1 TC)
Group XIIA secretory phospholipase A2 130
Neutral alpha-glucosidase AB 363 Y(1)
MESD 58
Total tyrosine phosphopeptides were isolated by anti-pTyr immunoprecipitation of tryptic digests of cell lysates or CM and analyzed by LC-MS/MS.
One hundred and forty unique phosphopeptides were identified, of which 48 (listed here) were mapped to proteins with canonical signal peptides, or
extracellular domains of transmembrane proteins, as annotated in UniprotKB. Peptides identified exclusively in conditioned medium are shaded in
bold. Tyrosine phosphorylation sites reported to occur in vivo in Phosphosite are marked with a ‘‘Y,’’ in parentheses the number of separate studies
is shown. ‘‘TC’’ designates sites that were detected in only in tissue culture cell lines. See also Table S1 and Data S1.
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Figure 6. Baculovirus Expressed VLK Phosphorylates Peptides and
Proteins
(A and B) Wild-type VLK, or VLK mutated at Lys66 (VLKKR) was purified from
CM of a baculovirus expression system and tested for peptide or protein
phosphorylation activity. (A) Biotinylated peptides were incubatedwith purified
VLK protein in the presence of 33[P]-g-ATP, captured on streptavidin
and counted by liquid scintillation counting. Errors bars represent standard
error of the mean from n = 3 samples. YPeptide: GRRYLQELQKEQ;
SPeptide:GRRSLQELQKEQ, TPeptide GRRTLQELQKEQ; HpxPeptide: pep-
tide derived from MMP1 hemopexin domain, QNVLHGYPKDI. (B) Purified
wild-type or mutant recombinant ERP29 phosphorylated by purified recom-
binant WT VLK or VLK mutated at Lys166 (KR) analyzed by Laemmli gel
electrophoresis and autoradiography. See also Figure S6.lack of a lumenal modifying enzyme required for optimal activity
in this system, or lack of an importantmammalianmodifying sub-
unit or cofactor. Elimination of the VLK signal peptide eliminates
VLK autophosphorylation (Figures 2 and 4), suggesting that
lumenal chaperones or other lumenal proteins are essential for
proper folding/activity of the secreted kinase domain. Phosphor-
ylation by VLK may also require secondary or tertiary structural
features of the substrate that are not recapitulated by the
test substrates used here. A third possibility is that lumenal tyro-
sine phosphatase activity may be much lower than cytosolic
tyrosine phosphatase activity, allowing a low turnover lumenal
tyrosine kinase to sustain significant lumenal/secreted tyrosine
phosphorylation. Defining the mechanism by which VLK activity
and substrate recognition are regulated will be an important area
for further investigation.
Relationship between VLK Substrates and Phenotype
Loss of VLK results in perinatal lethality with defects in skeletal,
lung, and craniofacial development (Imuta et al., 2009; Kinoshita
et al., 2009; Melvin et al., 2013; Probst et al., 2013). During
embryogenesis, VLK is expressed strongly in mesenchymal
condensations in bone, lung, and elsewhere and is broadly
expressed at lower levels in the adult (Kinoshita et al., 2009)
(Imuta et al., 2009). In human genome-wide association studies
(GWAS), VLK has been correlated with variations in bone
density, consistent with a role in skeletal development or
homeostasis (Hsu and Kiel, 2012). At the cellular level, the bestcharacterized defect in VLK null animals is in the differentiation
of chondrocytes in long bones (Imuta et al., 2009; Kinoshita
et al., 2009; Probst et al., 2013). Our studies identify a variety
of VLK substrates with established roles in skeletal develop-
ment, including type I collagen (Prockop, 1985), MMP13 (Stick-
ens et al., 2004), MIA3 (an essential collagen chaperone) (Wilson
et al., 2011), and MESD (a chaperone for the wnt receptor LRP5/
6) (Hsieh et al., 2003; Zhang et al., 2004). At this point, it is not
possible to assess whether the VLK null phenotype reflects
a major functional alteration in one or two key substrates, or
more subtle changes in a broad set of functionally interacting
substrates that collectively impact chondrocyte differentiation.
Our work also suggests a role for VLK in platelet function. VLK
protein is present in greater relative abundance in platelets
than in any other cell type we have examined, and is quantita-
tively released following stimulation of platelet degranulation.
Proteins secreted following platelet degranulation regulate
thrombosis, angiogenesis, inflammation, and tissue remodeling
during wound healing and tumorigenesis (Blair and Flaumenhaft,
2009; Harrison and Cramer, 1993). MMP1, which we have found
to be directly phosphorylated on tyrosine by VLK, is also cose-
creted from platelets with VLK, and is tyrosine phosphorylated
in this releasate (Figure 4D) as well as in vivo (Raijmakers et al.,
2010). MMP1 has a role both in platelet activation itself (San-
tos-Martı´nez et al., 2008) and in tissue remodeling associated
with wound healing (Raffetto and Khalil, 2008). In addition,
a variety of secreted proteins involved in the regulation of throm-
bosis are tyrosine phosphorylated in vivo (Hornbeck et al., 2012),
suggesting a potential role for secreted tyrosine kinase activity in
the control of thrombosis.
Potential Functions of VLK Phosphorylation Sites
The number and diversity of VLK phosphorylation sites that we
have identified makes it difficult to generalize regarding the
potential function of these phosphorylations. In a number of in-
stances, however, existing structural or functional information
points to specific roles for some of the tyrosine phosphorylations
we have found. The tyrosine phosphorylation in osteopontin, for
example, occurs in the middle of the integrin alpha9beta1 bind-
ing sequence SVVY*GLR and the addition of a charged phos-
phate in the middle of this short recognition site would be
strongly predicted to modulate integrin binding (Yokasaki and
Sheppard, 2000). The phosphorylation site in Type I collagen
occurs 2 amino acids N-terminal to the C-propeptide maturation
site (Kessler et al., 1996), pointing to a role for tyrosine phosphor-
ylation in collagen maturation.
Resident ER chaperones comprise a significant portion of
VLK substrates, suggesting that at least one function of VLK
is to modulate the secretory pathway. In the cases of the ER
chaperones MESD and ERP29, the tyrosines that we have
found to be phosphorylated are each established to have an
essential role in the interaction of these chaperones with spe-
cific substrates (Barak et al., 2009; Chen et al., 2010; Chen
et al., 2011), also indicating a role for phosphorylation in the
modulation of core protein function. Kinoshita et al. previously
reported that ectopic VLK expression reduced the overall rate
of VSVG progression through the secretory pathway (Kinoshita
et al., 2009), but this effect was seen equally with expression ofCell 158, 1033–1044, August 28, 2014 ª2014 Elsevier Inc. 1041
WT VLK and VLKKM, the latter of which we have found to be
inactive as a protein kinase. This general effect on secretion
therefore appears not to be associated with the catalytic activity
of VLK, but whether VLK selectively modifies chaperone func-
tion by phosphorylation remains an open question. Ectopically
expressed VLK has been reported to colocalize with Golgi
markers in immunohistochemical analysis (Kinoshita et al.,
2009). The abundant phosphorylation of ER resident proteins
we find in VLK expressing cells indicates that VLK is either pre-
sent and active in the ER or that it phosphorylates these pro-
teins in the Golgi during cycling between these compartments.
Interestingly, we find that VLK mutants that lack kinase activity
are no longer efficiently secreted from the cell, suggesting that
the catalytic activity of VLK modulates its own progression
through the secretory pathway.
Does VLK Function in the Secretory Pathway, or Outside
the Cell, or Both?
The characterization of FAM20C as an active serine kinase in the
Golgi apparatus provides a clear precedent that ATP dependent
protein phosphorylation can take place in the secretory appa-
ratus (Tagliabracci et al., 2012; Yalak and Vogel, 2012). Under
the conditions of our experiments in fibroblasts, there is no sig-
nificant source of ATP outside the cell, and therefore the VLK
phosphorylations we observe in these cells are likely to take
place within the secretory pathway. In platelets, however, dense
granules provide an abundant local source of extracellular ATP
following stimulation of secretion (McNicol and Israels, 1999).
We find that this endogenous ATP pool can sustain de novo tyro-
sine phosphorylation of secreted proteins in platelet releasate
(Figure 3B) indicating that secreted tyrosine kinase activity can
be supported by an endogenous source of extracellular ATP.
The concentration of ATP in platelet dense granules is estimated
to be 0.1–1M (Gordon, 1986; McNicol and Israels, 1999), and the
local concentration of ATP following degranulation in thrombo-
ses has been estimated to be well within the range required
for protein kinase activity (Gordon, 1986). The corelease of
VLK and ATP from platelets therefore provides the first plausible
example of de novo tyrosine phosphorylation in the extracellular
environment. ATP release from a broad range of both excitable
and nonexcitable cell types is also well known, and has been
proposed to support extracellular kinase activity (Praetorius
and Leipziger, 2009; Yalak and Vogel, 2012). Extracellular ATP
has also been reported to be elevated in the tumormicroenviron-
ment (Pellegatti et al., 2008) and to have a variety of protumori-
genic properties (Braganhol et al., 2013; Stagg and Smyth,
2010). Tyrosine phosphorylation on ER-resident proteins such
as ERP29 in vitro and in vivo indicates that endogenous VLK
has significant activity intracellularly in the secretory pathway,
but the regulated secretion of active VLK from platelets points
strongly to a significant role for VLK in the extracellular environ-
ment as well.
Patterns of Secreted Tyrosine Phosphorylation In Vivo
A striking feature of tyrosine phosphorylation of secreted pro-
teins in vivo is the conservation of phosphorylation sites in spe-
cific structural motifs in distantly related proteins. In addition to
the hemopexin domains noted in the Introduction, immunoglob-1042 Cell 158, 1033–1044, August 28, 2014 ª2014 Elsevier Inc.ulin (IG) domains, fibronectin (FN3) domains, and VWA domains,
are phosphorylated on tyrosine in multiple proteins, and these
phosphorylations can be localized to conserved structural fea-
tures within the domain (Figure S1). Conserved tyrosine phos-
phorylation of modular domains in ECM proteins (Hynes and
Naba, 2012) in vivo can be found in many additional domain
classes (e.g., CUB, TSP1, FN1, and FN2), but in these cases
insufficient structural information is available to place the phos-
phorylations relative to a common structural feature. While VLK
may be responsible for many of these phosphorylations, addi-
tional secreted kinases may be responsible for the full spectrum
of secreted tyrosine phosphorylations reported in vivo. Bio-
informatic work has identified several other putative secreted
proteins with significant similarity to VLK, suggesting that the
secreted protein kinome may still be far from complete (Dudkie-
wicz et al., 2013; Tagliabracci et al., 2013).
CONCLUSION
Ourwork places VLKwith FAM20C asmembers of a new class of
regulator of extracellular proteins, the secreted protein kinases.
Fam20C and VLK are evolutionarily more distant from one
another than they are from canonical cytoplasmic kinases, sug-
gesting that the evolution of multiple secreted kinases occurred
as independent events rather than divergence from a primordial
secreted kinase. The breadth and conservation of extracellular
structural and regulatory proteins that are found to be phosphor-
ylated in vivo makes it likely that defining the physiological roles
of secreted protein kinases will have a major impact on our
understanding of both normal tissue homeostasis and disease
pathogenesis.
EXPERIMENTAL PROCEDURES
Proteinase K Protection Assay
Cells were incubated in an isotonic extraction buffer and lysed using a Dounce
homogenizer and incubated in the presence of proteinase K alone or in com-
bination with 1% NP40. Proteolysis was terminated with PMSF and samples
analyzed by western blot.
Analysis of Ectopically Expressed VLK with Candidate Substrates
293T cells were transfected with cDNAs encoding wild-type or mutant VLK
constructs with or without cotransfection of candidate epitope tagged sub-
strates. After 24–48 hr cell lysates or CM were immunoprecipitated with anti-
tag antibody and analyzed for total expression or tyrosine phosphorylation
by western blot.
Microscopy
Platelets were fixed in 4% formaldehyde and centrifuged onto poly-L-lysine
(1 mg/ml)-coated coverslides, and analyzed for immunofluorescence with
anti-VLK antibody by scanning confocal microscopy as described in Extended
Experimental Procedures. Rapid-freeze immunogold electron microscopy of
washed human platelets was performed as previously described (Italiano
et al., 1999).
Platelet Release Assay
Whole bloodwas collected and platelets were isolated as previously described
(Thon et al., 2012). Platelets were treated with 0.2 mM phorbol-12-myristate-
13-acetate (PMA) or 0.5 mM thrombin-receptor activating peptide (TRAP) to
induce degranulation. After 4 min of treatment, cells were removed by centri-
fugation, and the supernatant (releasate) was treated with ATP, apyrase, or
anti-VLK antibody as described in the legend to Figure 3.
Kinase Assays
Mus musculus VLK (amino acids 55–492) was cloned into a modified pl-sec-
SUMOstar vector (LifeSensors) containing a tobacco etch virus (TEV) cleavage
site, and recombinant protein purified from CM as described in Extended
Experimental Procedures. For peptide kinase assays, 0.1 mg of purified recom-
binant protein was incubated with 5 mM 33[P]-g-ATP, 5 mM MgCl2, 0.5 mM
CaCl2, 50 mM Tris pH 7.5, and 1 mM biotinylated peptide, and then bio-
tinylated peptide was collected on streptavidin agarose and counted in a liquid
scintillation counter. For ERP29 phosphorylation assays, purified wild-type or
mutant ERP29 was assayed as substrate for phosphorylation by purified VLK
as described above, and analyzed by Laemmli gel electrophoresis and
autoradiography.
Mass Spectrometry
K4 fibroblasts stably expressing retrovirally transduced wild-type VLK
or VLKKM were lysed with urea lysis buffer, digested with trypsin, and tyro-
sine phosphopeptides isolated by immunoprecipitation and analyzed as
described in Extended Experimental Procedures. CM from transduced fibro-
blasts was precipitated with TCA and then solubilized and analyzed as for
cell lysates.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, one table, and one data file and can be found with this article online
at http://dx.doi.org/10.1016/j.cell.2014.06.048.
ACKNOWLEDGMENTS
The authors would like to thank Min Yuan for help with mass spectrometry
experiments, Peter Hornbeck (Cell Signaling Technologies) for valuable
discussions, Ross Okazaki and Rajesh Kulenthirarajan for platelet isolation,
and Shin-Ichi Nishikawa (RIKEN) for cDNAs encoding wild-type mouse VLK
and VLKKM. This work was supported in part by the National Institutes
of Health grants GM089885 and DE024312 (M.W.), Hl68130 (J.E.I.),
1K99HL114719-01A1 (J.N.T), 5P30CA006516, 5P01CA120964, NIH shared
instrumentation grant 1S10OD010612 (J.M.A.), DK 18024, and DK 18849
(J.E.D.), and grants from the Korean Government to C.Y.Y. (NRF
2012R1A5A1048236 and 2012R1A2A2A01046485, Next Generation BioGreen
21 Program PJ00812701). M.R.B. was supported by a Swiss National Science
Foundation fellowship.
Received: January 13, 2014
Revised: May 6, 2014
Accepted: June 20, 2014
Published: August 28, 2014
REFERENCES
Ahn, H.S., Foster, C., Boykow, G., Arik, L., Smith-Torhan, A., Hesk, D., and
Chatterjee, M. (1997). Binding of a thrombin receptor tethered ligand analogue
to human platelet thrombin receptor. Mol. Pharmacol. 51, 350–356.
Bai, Y., Li, J., Fang, B., Edwards, A., Zhang, G., Bui, M., Eschrich, S., Altiok, S.,
Koomen, J., and Haura, E.B. (2012). Phosphoproteomics identifies driver tyro-
sine kinases in sarcoma cell lines and tumors. Cancer Res. 72, 2501–2511.
Ballif, B.A., Carey, G.R., Sunyaev, S.R., and Gygi, S.P. (2008). Large-scale
identification and evolution indexing of tyrosine phosphorylation sites from
murine brain. J. Proteome Res. 7, 311–318.
Barak, N.N., Neumann, P., Sevvana, M., Schutkowski, M., Naumann, K.,
Malesevic, M., Reichardt, H., Fischer, G., Stubbs, M.T., and Ferrari, D.M.
(2009). Crystal structure and functional analysis of the protein disulfide isom-
erase-related protein ERp29. J. Mol. Biol. 385, 1630–1642.
Barnewitz, K., Guo, C., Sevvana, M., Ma, Q., Sheldrick, G.M., So¨ling, H.D., and
Ferrari, D.M. (2004). Mapping of a substrate binding site in the protein disulfide
isomerase-related chaperone wind based on protein function and crystal
structure. J. Biol. Chem. 279, 39829–39837.Blair, P., and Flaumenhaft, R. (2009). Platelet alpha-granules: basic biology
and clinical correlates. Blood Rev. 23, 177–189.
Braganhol, E., Wink, M.R., Lenz, G., and Battastini, A.M. (2013). Purinergic
signaling in glioma progression. Adv. Exp. Med. Biol. 986, 81–102.
Breitkopf, S.B., and Asara, J.M. (2012). Determining in vivo phosphorylation
sites using mass spectrometry. Curr Protoc Mol Biol Chapter 18, Unit18 19
11-27.
Brown, J., Novak, E.K., Takeuchi, K., Moore, K., Medda, S., and Swank, R.T.
(1987). Lumenal location of the microsomal beta-glucuronidase-egasyn
complex. J. Cell Biol. 105, 1571–1578.
Chen, J., Li, Q., Liu, C.C., Zhou, P., Bu, G., andWang, J. (2010). NMR structure
note: solution structure of the core domain of MESD that is essential for proper
folding of LRP5/6. J. Biomol. NMR 47, 283–288.
Chen, J., Liu, C.C., Li, Q., Nowak, C., Bu, G., and Wang, J. (2011). Two
structural and functional domains of MESD required for proper folding and
trafficking of LRP5/6. Structure 19, 313–323.
Ding, V.M., Boersema, P.J., Foong, L.Y., Preisinger, C., Koh, G., Natarajan, S.,
Lee, D.Y., Boekhorst, J., Snel, B., Lemeer, S., et al. (2011). Tyrosine phosphor-
ylation profiling in FGF-2 stimulated human embryonic stem cells. PLoS ONE
6, e17538.
Dudkiewicz, M., Lenart, A., and Paw1owski, K. (2013). A novel predicted
calcium-regulated kinase family implicated in neurological disorders. PLoS
ONE 8, e66427.
Faber, H.R., Groom, C.R., Baker, H.M., Morgan, W.T., Smith, A., and Baker,
E.N. (1995). 1.8 A crystal structure of the C-terminal domain of rabbit serum
haemopexin. Structure 3, 551–559.
Gomis-Ru¨th, F.X., Gohlke, U., Betz, M., Kna¨uper, V., Murphy, G., Lo´pez-Otı´n,
C., and Bode, W. (1996). The helping hand of collagenase-3 (MMP-13): 2.7 A
crystal structure of its C-terminal haemopexin-like domain. J. Mol. Biol. 264,
556–566.
Gonc¸alves, L., Filipe, M., Marques, S., Salgueiro, A.M., Becker, J.D., and Belo,
J.A. (2011). Identification and functional analysis of novel genes expressed
in the Anterior Visceral Endoderm. Int. J. Dev. Biol. 55, 281–295.
Gordon, J.L. (1986). Extracellular ATP: effects, sources and fate. Biochem. J.
233, 309–319.
Gu, T.L., Deng, X., Huang, F., Tucker, M., Crosby, K., Rimkunas, V., Wang, Y.,
Deng, G., Zhu, L., Tan, Z., et al. (2011). Survey of tyrosine kinase signaling
reveals ROS kinase fusions in human cholangiocarcinoma. PLoS ONE 6,
e15640.
Guo, A., Ville´n, J., Kornhauser, J., Lee, K.A., Stokes, M.P., Rikova, K.,
Possemato, A., Nardone, J., Innocenti, G., Wetzel, R., et al. (2008). Signaling
networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci.
USA 105, 692–697.
Hanks, S.K. (2003). Genomic analysis of the eukaryotic protein kinase super-
family: a perspective. Genome Biol. 4, 111.
Harrison, P., and Cramer, E.M. (1993). Platelet alpha-granules. Blood Rev. 7,
52–62.
Hornbeck, P.V., Kornhauser, J.M., Tkachev, S., Zhang, B., Skrzypek, E., Mur-
ray, B., Latham, V., and Sullivan, M. (2012). PhosphoSitePlus: a comprehen-
sive resource for investigating the structure and function of experimentally
determined post-translational modifications in man and mouse. Nucleic Acids
Res. 40, D261–D270.
Horton, P., Park, K.J., Obayashi, T., Fujita, N., Harada, H., Adams-Collier, C.J.,
and Nakai, K. (2007). WoLF PSORT: protein localization predictor. Nucleic
Acids Res. 35 (Web Server issue), W585–W587.
Hsieh, J.C., Lee, L., Zhang, L., Wefer, S., Brown, K., DeRossi, C., Wines, M.E.,
Rosenquist, T., and Holdener, B.C. (2003). Mesd encodes an LRP5/6
chaperone essential for specification of mouse embryonic polarity. Cell 112,
355–367.
Hsu, Y.H., and Kiel, D.P. (2012). Clinical review: Genome-wide association
studies of skeletal phenotypes: what we have learned and where we are head-
ed. J. Clin. Endocrinol. Metab. 97, E1958–E1977.Cell 158, 1033–1044, August 28, 2014 ª2014 Elsevier Inc. 1043
Hynes, R.O., and Naba, A. (2012). Overview of the matrisome—an inventory of
extracellular matrix constituents and functions. Cold Spring Harb. Perspect.
Biol. 4, a004903.
Imuta, Y., Nishioka, N., Kiyonari, H., and Sasaki, H. (2009). Short limbs, cleft
palate, and delayed formation of flat proliferative chondrocytes in mice with
targeted disruption of a putative protein kinase gene, Pkdcc (AW548124).
Dev. Dyn. 238, 210–222.
Italiano, J.E., Jr., Lecine, P., Shivdasani, R.A., and Hartwig, J.H. (1999). Blood
platelets are assembled principally at the ends of proplatelet processes pro-
duced by differentiated megakaryocytes. J. Cell Biol. 147, 1299–1312.
Jozic, D., Bourenkov, G., Lim, N.H., Visse, R., Nagase, H., Bode, W., andMas-
kos, K. (2005). X-ray structure of human proMMP-1: new insights into procol-
lagenase activation and collagen binding. J. Biol. Chem. 280, 9578–9585.
Kessler, E., Takahara, K., Biniaminov, L., Brusel, M., and Greenspan, D.S.
(1996). Bone morphogenetic protein-1: the type I procollagen C-proteinase.
Science 271, 360–362.
Kinoshita, M., Era, T., Jakt, L.M., and Nishikawa, S. (2009). The novel protein
kinase Vlk is essential for stromal function of mesenchymal cells. Development
136, 2069–2079.
Lu, P., Takai, K.,Weaver, V.M., andWerb, Z. (2011). Extracellular matrix degra-
dation and remodeling in development and disease. Cold Spring Harb. Per-
spect. Biol. 3, pii: a005058.
McNicol, A., and Israels, S.J. (1999). Platelet dense granules: structure, func-
tion and implications for haemostasis. Thromb. Res. 95, 1–18.
Melvin, V.S., Feng, W., Hernandez-Lagunas, L., Artinger, K.B., andWilliams, T.
(2013). A morpholino-based screen to identify novel genes involved in cranio-
facial morphogenesis. Dev. Dyn. 242, 817–831.
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., and Di Virgi-
lio, F. (2008). Increased level of extracellular ATP at tumor sites: in vivo imaging
with plasma membrane luciferase. PLoS ONE 3, e2599.
Petersen, T.N., Brunak, S., von Heijne, G., and Nielsen, H. (2011). SignalP 4.0:
discriminating signal peptides from transmembrane regions. Nat. Methods 8,
785–786.
Praetorius, H.A., and Leipziger, J. (2009). ATP release from non-excitable cells.
Purinergic Signal. 5, 433–446.
Probst, S., Zeller, R., and Zuniga, A. (2013). The hedgehog target Vlk geneti-
cally interacts with Gli3 to regulate chondrocyte differentiation during mouse
long bone development. Differentiation 85, 121–130.
Prockop, D.J. (1985). Mutations in collagen genes. Consequences for rare and
common diseases. J. Clin. Invest. 75, 783–787.
Raffetto, J.D., and Khalil, R.A. (2008). Matrix metalloproteinases and their in-
hibitors in vascular remodeling and vascular disease. Biochem. Pharmacol.
75, 346–359.
Raijmakers, R., Kraiczek, K., de Jong, A.P., Mohammed, S., and Heck, A.J.
(2010). Exploring the human leukocyte phosphoproteome using a microfluidic1044 Cell 158, 1033–1044, August 28, 2014 ª2014 Elsevier Inc.reversed-phase-TiO2-reversed-phase high-performance liquid chromatog-
raphy phosphochip coupled to a quadrupole time-of-flight mass spectrom-
eter. Anal. Chem. 82, 824–832.
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J.,
Lee, K., Reeves, C., Li, Y., et al. (2007). Global survey of phosphotyrosine
signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190–1203.
Rinschen, M.M., Yu, M.J., Wang, G., Boja, E.S., Hoffert, J.D., Pisitkun, T., and
Knepper, M.A. (2010). Quantitative phosphoproteomic analysis reveals vaso-
pressin V2-receptor-dependent signaling pathways in renal collecting duct
cells. Proc. Natl. Acad. Sci. USA 107, 3882–3887.
Rozenvayn, N., and Flaumenhaft, R. (2003). Protein kinase C mediates trans-
location of type II phosphatidylinositol 5-phosphate 4-kinase required for
platelet alpha-granule secretion. J. Biol. Chem. 278, 8126–8134.
Santos-Martı´nez, M.J., Medina, C., Jurasz, P., and Radomski, M.W. (2008).
Role of metalloproteinases in platelet function. Thromb. Res. 121, 535–542.
Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D., and Sawyers, C.L. (2004).
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305,
399–401.
Stagg, J., and Smyth, M.J. (2010). Extracellular adenosine triphosphate and
adenosine in cancer. Oncogene 29, 5346–5358.
Stickens, D., Behonick, D.J., Ortega, N., Heyer, B., Hartenstein, B., Yu, Y.,
Fosang, A.J., Schorpp-Kistner, M., Angel, P., and Werb, Z. (2004). Altered
endochondral bone development in matrix metalloproteinase 13-deficient
mice. Development 131, 5883–5895.
Tagliabracci, V.S., Engel, J.L., Wen, J., Wiley, S.E., Worby, C.A., Kinch, L.N.,
Xiao, J., Grishin, N.V., and Dixon, J.E. (2012). Secreted kinase phosphorylates
extracellular proteins that regulate biomineralization. Science 336, 1150–1153.
Tagliabracci, V.S., Pinna, L.A., and Dixon, J.E. (2013). Secreted protein
kinases. Trends Biochem. Sci. 38, 121–130.
Thon, J.N., Macleod, H., Begonja, A.J., Zhu, J., Lee, K.C., Mogilner, A., Hart-
wig, J.H., and Italiano, J.E., Jr. (2012). Microtubule and cortical forces deter-
mine platelet size during vascular platelet production. Nat Commun 3, 852.
Wilson, D.G., Phamluong, K., Li, L., Sun, M., Cao, T.C., Liu, P.S., Modrusan, Z.,
Sandoval, W.N., Rangell, L., Carano, R.A., et al. (2011). Global defects
in collagen secretion in a Mia3/TANGO1 knockout mouse. J. Cell Biol. 193,
935–951.
Yalak, G., and Vogel, V. (2012). Extracellular phosphorylation and phos-
phorylated proteins: not just curiosities but physiologically important. Sci.
Signal. 5, re7.
Yokasaki, Y., and Sheppard, D. (2000). Mapping of the cryptic integrin-binding
site in osteopontin suggests a newmechanismbywhich thrombin can regulate
inflammation and tissue repair. Trends Cardiovasc. Med. 10, 155–159.
Zhang, Y., Wang, Y., Li, X., Zhang, J., Mao, J., Li, Z., Zheng, J., Li, L., Harris, S.,
and Wu, D. (2004). The LRP5 high-bone-mass G171V mutation disrupts LRP5
interaction with Mesd. Mol. Cell. Biol. 24, 4677–4684.
